Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Tobi Klar

Dermatology Larchmont, NY Medical Doctor

NPI 1609934264 CMS profile 27930

2345 Boston Post Road, Larchmont, NY 10538

Open in the dashboard

General payments

$4,112

177 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Tobi Klar of Larchmont, NY is reported in the CMS Open Payments database as having received $4,112 across 177 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 60th percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,540 78
2024 General $1,269 43
2023 General $812 33
2022 General $248 10
2021 General $108 5
2020 General $33 2
2019 General $101 6

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Tobi Klar
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Tobi Klar were reported at $1,540. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Tobi Klar Dermatology median Middle half National median
2019 $101 $454 $129–$1,240 $163
2020 $33 $235 $81–$756 $114
2021 $108 $377 $108–$1,108 $132
2022 $248 $514 $143–$1,391 $149
2023 $812 $607 $159–$1,674 $160
2024 $1,269 $751 $204–$1,903 $164
2025 $1,540 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Janssen Biotech, Inc. $792 29 payments
  2. Lilly USA, LLC $488 19 payments
  3. Dermavant Sciences, Inc. $340 14 payments
  4. Incyte Corporation $299 23 payments
  5. Regeneron Healthcare Solutions, Inc. $297 9 payments
  6. Pfizer Inc. $290 16 payments
  7. Botanix SB Inc $283 11 payments
  8. Genzyme Corporation $258 8 payments
  9. Novartis Pharmaceuticals Corporation $218 12 payments
  10. E.R. Squibb & Sons, L.L.C. $207 11 payments
  11. Other $640 25 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,783 173 payments
  2. Education $328 4 payments
Products named General payments · program years 2019–2025
  1. TREMFYA $725 26 payments
  2. EBGLYSS $302 12 payments
  3. OPZELURA $299 23 payments
  4. CIBINQO $290 16 payments
  5. DUPIXENT Immunology $287 9 payments
  6. SOFDRA $283 11 payments
  7. LITFULO $274 15 payments
  8. TALTZ $215 9 payments
  9. SOTYKTU $207 11 payments
  10. DUPIXENT Inflammation And Immunology $200 6 payments
  11. Other $1,700 77 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 36 drugs

Part D claims

1,370

Median for Dermatology: 534

Drug cost

$109,899

Median for Dermatology: $67,151

Branded share of claims

13.5%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Syringe Dupilumab Brand 14 $51,037
Tacrolimus Generic 51 $18,067
Ivermectin Generic 22 $7,066
Fluorouracil Generic 57 $3,334
Fluocinonide Generic 64 $3,153
Ciclopirox Ciclopirox Olamine Brand 61 $2,489
Calcipotriene Generic 16 $2,384
Tretinoin Generic 28 $2,215
Ketoconazole Generic 130 $2,002
Nystatin Generic 97 $1,992

The 10 drugs with the highest cost, of 36 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 46 billing codes

Paid by Medicare

$268,373

Of which drugs: $227

Medicare patients

646

Average age 76

Services billed

3,281

433 women, 213 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 67%
Arthritis 47%
Diabetes 22%
Ischemic heart disease 22%
Osteoporosis 21%
Cancer 18%
Atrial fibrillation 14%
Depression 13%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 82 292 $220

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 14 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TREMFYA
  • Janssen Biotech, Inc. $273
$273 — —
DUPIXENT
  • GENZYME CORPORATION $111
  • Regeneron Healthcare Solutions, Inc. $76
$187 14 —
SOTYKTU
  • E.R. Squibb & Sons, L.L.C. $140
$140 — —
TALTZ
  • Lilly USA, LLC $83
$83 — —
OLUMIANT
  • Lilly USA, LLC $51
$51 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 14 in the dashboard with a free account

Records

177 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record